
HG-TRZ-2
Lot TIR10-0803 · 99.80 %- Lot-matched certificate of analysis, identity and purity by HPLC and mass spec
- Ships within 1 business day from the U.S., tracked, in protective packaging
- Research use only. Not for human or animal use
- Ships within 1 business day, tracked, protective packaging
- 2-Day $12.99, free at $1,000 and over
- Overnight $250
- Certificate of analysis available on request
- ≥99% purity specification, HPLC & mass-spec verified at source
- Ships from a U.S. facility within 1 business day
- Secure card checkout on our payment partner's page, 20% already in the total
Complete your setup
Lyophilized peptides need bacteriostatic water and sterile lab supplies to reconstitute. Add the essentials in one click.
HG-TRZ-2In your orderLY3298176 is a synthetic 39-residue dual GIP and GLP-1 receptor agonist built on a fatty-acid-modified peptide backbone. Published pharmacology research examines how engaging both incretin receptors at once affects glucose handling and body weight in cell-based signaling assays and mouse models, distinguishing it from single-receptor GLP-1 agonists studied in earlier incretin research.
LY3298176 is a 39-amino-acid peptide that activates both the GIP and GLP-1 receptors. Its dual activity makes it a standard tool for comparing single-pathway and dual-pathway incretin signaling.
Common research applications include:
- Dual incretin receptor research
- Metabolic-rate and adiposity models
- Receptor selectivity and binding studies
Specifications
- Class: Dual GIP / GLP-1 receptor agonist
- Form: lyophilized powder in a sealed glass vial
- Available sizes: 10 mg, 20 mg, 30 mg, 60 mg, 100 mg
- Purity: verified at 99% or higher by HPLC, identity confirmed by mass spectrometry
- Testing: every lot is third-party tested, with a lot-matched Certificate of Analysis available on request
- supplied by a U.S. lab
- Storage: keep sealed, cool, dry and away from light; refrigerate after reconstitution
For laboratory research use only. This product is not for human or veterinary use, is not a drug, food or cosmetic, and is not intended to diagnose, treat, cure or prevent any disease.
What the Literature Studies
Coskun and colleagues described LY3298176's discovery pharmacology in a 2018 paper in Molecular Metabolism. In vitro, the compound activated both GIP and GLP-1 receptor signaling in cell lines expressing the recombinant or endogenous receptors. In mice, LY3298176 produced glucose-dependent insulin secretion and improved glucose tolerance by acting on both receptors, and chronic administration decreased body weight and food intake to a significantly greater degree than a GLP-1 receptor agonist alone in the same mouse model. The authors attribute this added effect to the GIP receptor component acting on top of established GLP-1 receptor pharmacology, which is the central mechanistic finding behind the dual-agonist design.
Specification and Handling
This lot is a 39-residue peptide with Aib substitutions and a Lys20 side chain conjugated to a gamma-Glu-(AEEA)2-C20 diacid, C-terminal amide, full sequence per the certificate of analysis. Molecular formula is C225H348N48O68 with a molecular weight of 4813.45. CAS number is 2023788-19-2. Supplied as a lyophilized powder, purity verified at 99% or greater by HPLC, identity confirmed by mass spectrometry, certificate of analysis for the lot available on request. The powder is soluble in bacteriostatic water. Sealed vials are stored at -20°C, protected from light and moisture; reconstituted solution is refrigerated at 2-8°C and split into single-use aliquots where practical.
Buying Notes
LY3298176 is available in 10 mg, 20 mg, 30 mg, 60 mg, and 100 mg lyophilized vials, the widest size range in this catalog's incretin category and a reflection of demand across research scales. The certificate of analysis for each lot reports HPLC purity and a mass spectrometry match to the 4813.45 theoretical mass, confirming the dual-agonist sequence and fatty-acid conjugation for that specific lot. For receptor-class comparisons, see the HG TRZ 2 research page for handling detail on this lot, and the LY3437943 VS LY3298176 VS NN9535 article for how the dual- and triple-agonist structures compare across the incretin literature.
Lots on file for HG-TRZ-2
One row per size. Purity by RP-HPLC, measured content against the stated amount, and the date the independent laboratory issued the certificate. Printed minimum ≥ 99.0 %.
| Size | Lot | Purity (RP-HPLC) | Measured content vs label | Certificate date | Results |
|---|---|---|---|---|---|
| 10 mg | TIR10-0803 | 99.80 % | 10.18 mg · stated 10 mg | Aug 17, 2026 | Lot results → |
| 20 mg | TIR20-0803 | 99.80 % | 20.77 mg · stated 20 mg | Aug 17, 2026 | Lot results → |
| 30 mg | TIR30-0803 | 99.85 % | 30.69 mg · stated 30 mg | Aug 17, 2026 | Lot results → |
| 60 mg | TIR60-0803 | 99.79 % | 61.11 mg · stated 60 mg | Aug 17, 2026 | Lot results → |
| 100 mg | TIR100-0803 | 99.85 % | 101.88 mg · stated 100 mg | Aug 17, 2026 | Lot results → |
Frequently Asked Questions
What two receptors does LY3298176 engage in published pharmacology?
LY3298176 activates both the GIP receptor and the GLP-1 receptor, confirmed in cell-based signaling assays in the 2018 Coskun paper. This dual engagement is the defining structural feature studied in that work.
What model showed a greater effect on body weight than a GLP-1 agonist alone?
The 2018 Molecular Metabolism paper reports that chronic administration of LY3298176 to mice reduced body weight and food intake significantly more than a GLP-1 receptor agonist alone in the same model. This comparison is the paper's key in vivo finding.
What does the Lys20 side chain modification do?
The Lys20 residue is conjugated to a gamma-Glu-(AEEA)2-C20 fatty diacid, a structural feature associated with extended circulation via albumin binding. The exact sequence and conjugation site are listed on the certificate of analysis.
Why does LY3298176 come in five different vial sizes?
The wider size range reflects the range of total peptide quantities researchers request for this compound relative to others in the incretin category. Each size shares the same purity grade and CAS number.
What does the certificate of analysis verify for a LY3298176 lot?
It reports HPLC purity at 99% or greater and a mass spectrometry check against the 4813.45 theoretical mass for the C225H348N48O68 formula. This confirms the peptide's identity and conjugation independent of any outcome claim.
Is HG-TRZ-2 third-party tested?
Yes. Every lot is tested for identity and purity at the source lab by HPLC and mass spectrometry against a ≥99% purity specification. The lot-matched certificate of analysis is on file and shown on this page.
Can I see the Certificate of Analysis before buying?
Yes. The certificate on file for the current lot is linked above, documenting identity, purity, and analytical results. Ask us for any other lot.
What does 'Research Use Only' mean?
This product is supplied strictly for laboratory and research use only (RUO). It is not a drug, food, supplement, or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure, or prevent any disease, or for human or veterinary consumption.
How is it shipped and stored?
Orders ship within 1 business day from our U.S. facility with tracking. Store the lyophilized material at −20°C, protected from light and moisture.


